Login / Signup

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

Hai-Yan TuJifeng FengMeiqi ShiJun ZhaoYuyan WangJianhua ChangJialei WangYing ChengJing ZhuEng-Huat TanKai LiYiping ZhangVictor LeeCheng-Ta YangWu-Chou SuDavid Chi-Leung LamB J SrinivasaSenthil RajappaChing-Liang HoKwok Chi LamYi HuShailesh Arjun BondardeXiaoqing LiuYahui TianZhiyi XueAgnieszka CsehDennis Chin-Lun HuangCaicun ZhouYi-Long Wu
Published in: Targeted oncology (2022)
NCT01953913 (1 October 2013).
Keyphrases